Atyr Pharma Inc (ATYR) concluded trading on Wednesday at a closing price of $5.53, with 4.36 million shares of worth about $24.09 million changed hands on the day. Half year performance of the stock remained positive as price took a surge of 38.94% during that period and on July 09, 2025 the price saw a gain of about 6.55%. Currently the company’s common shares owned by public are about 89.00M shares, out of which, 86.06M shares are available for trading.
Stock saw a price change of 7.80% in past 5 days and over the past one month there was a price change of 2.79%. Year-to-date (YTD), ATYR shares are showing a performance of 266.23% which increased to 52.76% when we look at its performance for past 12 months. Over the period of past 52 weeks, stock dropped to lowest price of $1.51 but also hit the highest price of $5.98 during that period. The average intraday trading volume for Atyr Pharma Inc shares is 2.29 million. The stock is currently trading 5.25% above its 20-day simple moving average (SMA20), while that difference is up 25.07% for SMA50 and it goes to 57.46% higher than SMA200.
Atyr Pharma Inc (NASDAQ: ATYR) currently have 89.00M outstanding shares and institutions hold larger chunk of about 68.68% of that.
The stock has a current market capitalization of $492.19M and its 3Y-monthly beta is at 0.95. It has posted earnings per share of -$0.81 in the same period. It has Quick Ratio of 7.79 while making debt-to-equity ratio of 0.17. Volatility of a stock is a metric used to know how much the price of that stock is under influence and for ATYR, volatility over the week remained 8.12% while standing at 7.73% over the month.
Analysts are in expectations that Atyr Pharma Inc (ATYR) stock would likely to be making an EPS of -0.18 in the current quarter, while forecast for next quarter EPS is -0.15 and it is -0.61 for next year. For the current quarter EPS, analysts have given the company a lowest target -0.25 which is -0.17 at the higher side of the target for the same. When we compare those targets with actual EPS, we find that company posted an EPS of -0.23 in the same quarter a year ago. Stock’s fiscal year EPS is expected to rise by 28.86% while it is estimated to increase by 0.45% in next year.
Digging deeper we find that several firms have released their research notes about the support levels of the stock. Most recent of them is a note released by Leerink Partners on February 18, 2025 offering an Outperform rating for the stock and assigned a target price of $16 to it. On October 04, 2024, Wells Fargo Initiated their recommendations, while on September 05, 2024, Jefferies Initiated their ratings for the stock with a price target of $9. Stock get a Perform rating from Oppenheimer on July 05, 2023.
